Development of the novel ACLY inhibitor 326E as a promising treatment for hypercholesterolemia
Authors:
Open Access
- 17 June 2022
- journal article
- research article
- Published by Elsevier in Acta Pharmaceutica Sinica B
- Vol. 13 (2) , 739-753
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82170872, 92057116)
- Chinese Academy of Sciences (XDA12040328)
- Science and Technology Commission of Shanghai Municipality (20S11903400)
- Natural Science Foundation of Shanghai Municipality (21ZR1475300)
This publication has 55 references indexed in Scilit:
- Acetylation Stabilizes ATP-Citrate Lyase to Promote Lipid Biosynthesis and Tumor GrowthMolecular Cell, 2013
- Liver X Receptor Agonist Modulation of Cholesterol Efflux in Mice With Intestine-Specific Deletion of Microsomal Triglyceride Transfer ProteinArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- Indices of Obesity and Cardiometabolic RiskHypertension, 2011
- Pharmacological strategies for lowering LDL cholesterol: statins and beyondNature Reviews Cardiology, 2011
- Deficiency in hepatic ATP-citrate lyase affects VLDL-triglyceride mobilization and liver fatty acid composition in miceJournal of Lipid Research, 2010
- Abrogation of hepatic ATP-citrate lyase protects against fatty liver and ameliorates hyperglycemia in leptin receptor-deficient mice #Hepatology, 2009
- Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9Nature Genetics, 2005
- ABCG5 and ABCG8 Are Obligate Heterodimers for Protein Trafficking and Biliary Cholesterol ExcretionJournal of Biological Chemistry, 2003
- Structural Mechanism for Statin Inhibition of HMG-CoA ReductaseScience, 2001
- Regulation of Hepatic De Novo Lipogenesis in HumansAnnual Review of Nutrition, 1996